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ABSTRACT
The splicing factor Sam68 is upregulated in many hu-
man cancers, including prostate cancer (PCa) where
it promotes cell proliferation and survival. Neverthe-
less, in spite of its frequent upregulation in can-
cer, the mechanism(s) underlying its expression are
largely unknown. Herein, bioinformatics analyses
identified the promoter region of the Sam68 gene
(KHDRBS1) and the proto-oncogenic transcription
factor c-MYC as a key regulator of Sam68 expression.
Upregulation of Sam68 and c-MYC correlate in PCa
patients. c-MYC directly binds to and activates the
Sam68 promoter. Furthermore, c-MYC affects pro-
ductive splicing of the nascent Sam68 transcript by
modulating the transcriptional elongation rate within
the gene. Importantly, c-MYC-dependent expression
of Sam68 is under the tight control of external cues,
such as androgens and/or mitogens. These findings
uncover an unexpected coordination of transcription
and splicing of Sam68 by c-MYC, which may repre-
sent a key step in PCa tumorigenesis.
INTRODUCTION
Prostate cancer (PCa) is among the most common tumors
in adult men (1). PCa onset and progression rely on andro-
gen receptor (AR) signaling and androgen deprivation ther-
apy (ADT) represents the most effective cure (2). However,
despite significant advances in treatments, PCa almost in-
evitably relapses with hormone-insensitive forms (CRPC)
that are currently incurable (2). Among the factors con-
tributing to PCa pathogenesis, aberrant splicing of cancer-
specific genes contributes by promoting isoforms involved
in growth, metastatic progression and hormone resistance
of PCa cells (3,4). For example, a constitutively active splice
variant of AR (AR-V7) is overexpressed in CRPC, where
it promotes cell proliferation and migration by regulat-
ing a specific subset of genes even under ADT conditions
(5). Likewise, the anti-apoptotic BCL-X long splice variant
(BCL-XL) confers chemotherapy resistance (6), whereas
the Cyclin D1b isoform promotes AR transcriptional activ-
ity (7). In support of their pro-oncogenic features, expres-
sion of these splice variants is linked to poor prognosis in
PCa patients (7–9).
Precursor messenger RNA (pre-mRNA) splicing is oper-
ated by the spliceosome, a complex ribonucleoprotein ma-
chinery that removes introns and ligates exons to yield the
mature mRNA (10). Although most exons are constitu-
tively spliced in the mRNA, others are subjected to regula-
tion through a process named alternative splicing (AS). Al-
ternative recognition of exons is due to the presence of cis-
regulatory RNA elements that recruit the spliceosome and
sequence-specific trans-acting splicing factors (10). More-
over, since splicing is tightly coupled to transcription, mech-
anisms impacting on the RNA polymerase II (RNAPII)
elongation rate, nucleosome positioning or histone modifi-
cations also contribute to exon recognition (10). These reg-
ulatory mechanisms are kept under tight control in the cell,
whereas their dysregulation contributes to the onset and
progression of human cancers (11,12), including PCa (3,4).
Splicing dysregulation is often determined by the altered
expression of specific splicing factors (11,12). An example is
provided by Sam68 (KHDRBS1), which is overexpressed in
PCa and other human cancers (13). Sam68 promotes cell-
cycle progression and survival to genotoxic stress of PCa
cells (14), likely through induction of oncogenic splice vari-
ants like BCL-XL, cyclin D1b, CD44 variants and AR-V7
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(3,4). Furthermore, Sam68 interacts with bothAR andAR-
V7, enhancing their transcriptional activity and androgen
signaling (15). However, in spite of its well described upreg-
ulation in human cancers (13), no studies have directly ad-
dressed the mechanisms underlying its transcriptional reg-
ulation.
Herein, by carrying out a bioinformatics search for tran-
scription factors that potentially regulate Sam68 expression
we have identified the proto-oncogene c-MYC (MYC) as
strong candidate. Our study documents the direct binding
of c-MYC to the Sam68 promoter region as well as its effect
on the transcriptional activation of the gene and productive
splicing of the nascent transcript. Furthermore, we provide
evidence that c-MYC-dependent expression of Sam68 is un-
der the tight control of external cues and linked to favorable
conditions, such as androgen and/or mitogen stimulation.
These findings uncover an unexpected coordination of tran-
scription and splicing of Sam68 by c-MYC, which may rep-
resent a vulnerable target for PCa treatment.
MATERIALS AND METHODS
Bioinformatics analyses
Sam68 promoter characterization was performed uti-
lizing bioinformatics tools present in UCSC Genome
Browser (https://genome.ucsc.edu; GRCh37/h19) and ana-
lyzing ChIP-seq data for RNAPII, H3K27Ac, H3K4Me1
and H3K4Me3 tracks from ENCODE project (https://
www.encodeproject.org). Chromatin State Segmentation
track displays a chromatin state segmentation from nine
human cell types learned by computationally integrating
ChIP-seq data for nine factors plus input using a Hidden
Markov Model. In UCSC Genome Browser, in silico anal-
ysis of Sam68 promoter was performed using ‘HMR Con-
served Transcription Factor Binding Site’ tool that use the
Transfac Matrix Database (v.7.0). c-MYC ChIP-seq anal-
yses was performed using ‘Transcription Factor ChIP-seq
(161 factors) fromENCODEwith Factorbookmotifs’ tool.
Tumor Prostate Cancer datasets analysis was carried out
utilizing Jenkins (GSE46691), Sawyers (GSE21034) and
Sueltman (GSE29079) published datasets (16–18). Gene
expression data for correlation analyses were downloaded
from R2 genomics analysis and visualization platform
(http://r2.amc.nl). Pearson’s correlation was used to evalu-
ate the association between Sam68 and c-MYC expression.
For gene expression analyses, the patients were divided into
two groups according to the median of c-MYC gene expres-
sion. Then, Z-scores value of Sam68 was calculated in each
sample and Mann–Whitney test was used to establish the
significance level of Sam68 between the two groups (19).
Plasmid constructs and oligonucleotides
Intergenic region, human wild-type and deletion mutants
of Sam68 and hnRNP A1 promoters were cloned in pGL3-
basic vector (Promega). Human c-MYC and MAX expres-
sion plasmids were cloned in pCDNA3 vector (Invitro-
gen, Life technologies). Site-directedmutagenesis on pGL3-
Sam68 promoter was performed using QuikChangeR II
XL Site-Directed Mutagenesis Kit according to manu-
facturer’s instruction (Stratagene). Sam68 minigene was
cloned into the EcoRI/SalI restriction sites of pCI vector
(Promega). All constructs were generated using genomic
DNA or cDNA isolated from LNCaP cells as template.
Inserts were amplified by the Phusion Hot Start High-
Fidelity DNA polymerase (Thermo Fisher Scientific) and
plasmids sequenced by Cycle Sequencing (Eurofins Ge-
nomics). Oligonucleotides used in this study are listed in the
Supplementary Table S1.
Cell lines maintenance and transfection
Human prostate cancer cell lines LNCaP and 22Rv1 were
cultured in RPMI 1640 medium (LONZA), while PC3 and
DU145 PCa cell lines and human embryonic kidney cell
line HEK293T were maintained in Dulbecco’s modified
Eagle’s medium (LONZA). All media were supplemented
with 10% Fetal Bovine Serum (FBS) (Gibco), penicillin
(50 U/ml)/streptomycin (50 g/ml) (Corning), 50 g/ml
gentamicin sulfate (Aurogene), 1% non-essential amino
acids (Euroclone), 10 mM Hepes (Euroclone) and 1 mM
sodium pyruvate (Aurogene). Cells were maintained in cul-
ture at 37◦C under 5% CO2 in a humidified incubator, no
longer than 3 months. Cell lines utilized were tested for
mycoplasma contamination usingMycoAlert Mycoplasma
Detection Kit (LONZA). LNCaP and HEK293T were
transfected with the indicated reporter or expression vec-
tors using Lipofectamine 2000 (Invitrogen) as previously
described (20). For c-MYC (double transfection) and splic-
ing factors (single transfection) RNAi experiments, PCa
cells were transfected with 40 nM siRNAs using Lipofec-
tamine RNAiMax (Invitrogen, Life technologies) accord-
ing to manufacturer’s instruction. Control and c-MYC siR-
NAs were purchased from Dharmacon (On target plus hu-
man c-MYC L-003282-02 and On target plus non targeting
pool D-001810-10) and Qiagen (Flexi Tube siRNA MYC
SI03101847 and Negative control SI03650325). Sequences
of control and splicing factors siRNAs were previously de-
scribed (20).
Cell treatments and proliferation analysis
Growth arrest was induced by culturing PCa cells in 0%
FBS and with 1 M Enzalutamide (MDV3100; Sigma-
Aldrich), or DMSO as vehicle control. For cell proliferation
assays, cells were pulsed with 30 MBrdU (Sigma-Aldrich)
for 30 min. After PBS washes, cells were collected, fixed
with 70% ethanol and stained with anti-BrdU antibody
(347580, BD Biosciences) and propidium iodide (Sigma-
Aldrich). Cell-cycle analysis was carried out using flow cy-
tometry (FACSCalibur, BD Biosciences) according to man-
ufacturer’s instructions.
Cell extracts and immunoblot analysis
Whole extract preparation was performed as previously
described (21). Briefly, cells were resuspended in lysis
buffer [50 mM Hepes, pH 7.4, 150 mM NaCl, 15 mM
MgCl2, 10% glycerol, 1 mM dithiothreitol, 20 mM -
glycerophosphate, 0.5mMNaVO4, protease inhibitor cock-
tail (Sigma-Aldrich), 0.5% Triton X-100]. After 10 min
of ice incubation, cell suspension was centrifuged for
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10 min at 12 000 × g at 4◦C and supernatant frac-
tions were collected. Samples were denatured in Laemmli
Sample buffer and 3–30 g of total extract was sepa-
rated on sodium dodecyl sulphate-polyacrylamide gelelec-
trophoresis (SDS-PAGE) and transferred to Polyvinyli-
dene Fluoride (PVDF) membranes. Western blot anal-
ysis was carried using the following antibodies: anti-
SAM68 (A302-110A, Bethyl Laboratories); anti--actin
(A2066, Sigma-Aldrich); anti--tubulin (T4026, Sigma-
Aldrich); anti-c-MYC (sc764, Santa Cruz Biotechnology);
anti-hnRNPA1 (sc32301, SantaCruzBiotechnology); anti-
MAX (sc2011, Santa Cruz Biotechnology); anti-hnRNP I
(sc16547 Santa Cruz Biotechnology); anti-hnRNP A2/B1
(sc393674, Santa Cruz Biotechnology); anti-GFP (sc9996,
Santa Cruz Biotechnology); Anti-RNA polymerase II
(sc899, Santa Cruz Biotechnology); anti-RNA polymerase
II subunit B1, clone 3E10 (phospho CTD Ser-2, 04-
1571,Millipore); anti-RNApolymerase II subunit B1, clone
3E8 (phospho-CTD Ser5; 04-1572, Millipore); anti-Flag
(F3165, Millipore); anti-hnRNP H and anti-hnRNP F
(kindly provided by Prof. B. Chabot, Universite´ de Sher-
brooke, Canada).
Luciferase-based report assay
Luciferase-based report assay was performed in HEK293T
cells as previously described (22). Briefly, HEK293T cells
were co-transfected with internal control (Renilla) and in-
dicated (Firefly) luciferase reporters in presence or not of c-
MYC, or MAX, expressing vectors. Luciferase assays were
carried out at the indicated time points using the Dual Lu-
ciferase Reporter assay (Promega). Data were normalized
for transfection efficiency by ratio between Firefly and Re-
nilla luciferase activity, and represented as fold activation
with respect to the control.
RNA extraction, gene expression and splicing assay analysis
RNA was extracted from cells using the Trizol reagent
according to manufacturer’s instructions (Invitrogen, Life
technologies) and treated with RNase-free DNase (Am-
bion). A total of 1 g of RNA was retrotranscribed
with M–MLV reverse transcriptase (Promega) and ran-
dom primers (Roche). Gene expression and splicing pat-
terns were evaluated by semi-quantitative (sqPCR) and
quantitative (qPCR) PCR analyses using 10 ng of cDNA
template. For splicing assay experiments, sqPCR analysis
was performed using the following cycles: 95◦C for 5 min
(1 cycle) −95◦C for 10 s, 56◦C for 10 s, 72◦C for 15 s
(28 or 35 cycles for minigene-derived or endogenous iso-
forms, respectively)− and a final extension at 72◦C for 5
min. The percentage Spliced-In Index (PSI/ ) was calcu-
lated from densitometric analysis of PCR products as 
= exon inclusion/ (exon inclusion + exon skipping) band
intensities. qPCR analysis was carried out using PowerUp
SYBR Green Master Mix (Applied Biosystems) and Ap-
plied Biosystems StepOnePlus Real-Time PCR system (Ap-
plied Biosystems) according to the manufacturer’s instruc-
tions.Quantitative evaluation of gene and Sam68-KH iso-
form expression was calculated relative to Histone 3 and
Sam68-KH, respectively, by Cq method (21).
Analysis of RNA polymerase II (RNAPII) transcrip-
tional rate on Sam68 pre-mRNA was performed as pre-
viously described (23). Briefly, LNCaP cells were grown
overnight on 60-mm plates to 70–80% confluency and
treated with 75 M of 5,6-Dichlorobenzimidazole 1-–D-
ribofuranoside (DRB; Sigma-Aldrich) in culture medium
for 6 h to reversibly halt transcription. After two washes
in phosphate buffered saline (PBS), cells were incubated in
fresh medium up to 30 min. Every 5 min cells were col-
lected for RNA isolation. Fold change of Sam68 exon1–
intron1 relative to exon8–intron8 expression was calculated
by Cq method (21).
Chromatin immunoprecipitation
ChIP experiments were performed as previously described
(22). Briefly, LNCaP cells were fixed by the addition of
1% (vol/vol) formaldehyde to the culture medium for 10
min at room temperature and then quenched in 125 mM
glycine for 5 min. Cells were washed three times in PBS
and lysed in nuclei extraction buffer (5 mM Pipes pH 8, 85
MmKCl, 0.5%NP40) for 2 h, at 4◦C under rotation. Lysate
was centrifuged at 1200 × g for 5 min at 4◦C. Nuclei pellet
was resuspended in sonication buffer (10 mM ethylenedi-
aminetetraacetic acid (EDTA) pH 8, 50 mM Tris–HCl pH
8, SDS 1%) and sonicated with Bioruptor (Dyagenode) to
yield chromatin size of ∼400 bp and insoluble debris was
removed by centrifugation. Cross-linked DNA was then
quantified, diluted 1:10 with dilution buffer (0.01% SDS,
1.1% Triton X100, 1.2 mM EDTA, 16.7 mM Tris/HCl pH
8.0, 167 mM NaCl) and incubated with 5 g of specific
c-MYC antibody (sc-764X, Santa Cruz Biotechnologies),
IgGs (Sigma-Aldrich) and no antibody, as a negative con-
trols, under rotation at 4◦Covernight. Dynabeads proteinG
(Invitrogen, Life technologies) were incubated with themix-
ture under rotation at 4◦C for 2 h, then washed and heated
at 65◦C overnight to reverse formaldehyde cross-links. Im-
munoprecipitated DNA was recovered according to stan-
dard procedures and analyzed by qPCRs. DNA associated
with c-MYC is represented as percentage of input, calcu-
lated by Cq method (21).
UV-crosslinked and RNA immunoprecipitation (CLIP) as-
says
UV-crosslinked and RNA immunoprecipitation (CLIP) as-
says were performed as previously described (24). Briefly,
cells were washed once with PBS, UV-irradiated (400
mJ/cm2) and collected by scraping in lysis buffer [50 mM
Tris pH 8, 100 mM NaCl, 1 mM MgCl2, 0.1 mM CaCl2,
1% NP40, 0.1% SDS, 0.5 mM Na3VO4, 1 mM dithiothre-
itol, protease inhibitor cocktail (Sigma-Aldrich), RNase in-
hibitor (Promega)]. After brief sonication, samples were in-
cubated with DNase-RNase free (Ambion) for 3 min at
37◦C and then centrifuged at 15000 × g for 3 min at 4◦C.
A total of 1 mg of supernatant (cell extract) was diluted to
1 ml with lysis buffer and immunoprecipitated with anti-
hnRNP F (kindly provided by Prof. B. Chabot, Universite´
de Sherbrooke, Canada) or IgGs (control) in the presence
of Dynabeads protein G (Invitrogen, Life technologies) and
10 l/ml of RNaseI 1:1000 (Ambion). Immunoprecipitates
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(IPs) were incubated for 2 h at 4◦C under rotation. After
two washes with high-salt buffer (50 mMTris–HCl, pH 7.4,
1 M NaCl, 1 mM EDTA, 1% Igepal CA-630, 0.1% SDS,
0.5% sodium deoxycholate) and Proteinase K buffer (100
mM Tris–HCl, pH 7.4, 50 mM NaCl, 10 mM EDTA), the
IPs were resuspended in Proteinase K buffer supplemented
with 50 g of Proteinase K and incubated 1 h at 55◦C.
RNA was isolated and retrotranscribed by standard proce-
dures. About 10% of cell extract (0.1 mg) was treated with
50 g of Proteinase K and RNA purified (input).
RESULTS
c-MYC binds the promoter region of Sam68
To identify the promoter region of the Sam68 gene
(KHDRBS1), we queried the UCSC Genome Browser
database (http://genome.ucsc.edu; GRCh37/h19) for RNA
polymerase II (RNAPII) occupancy and chromatin features
of active transcription within the gene and in the upstream
intergenic region (∼20 kilobases). Chromatin immunopre-
cipitation (ChIP) sequencing datasets from seven human
cell lines revealed that RNAPII peaks are present in the
region spanning approximately −400 and +300 base pairs
(bp) from the transcription start site (TSS) (Figure 1A and
Supplementary Figure S1A). RNAPII peaks are flanked
by deposition of histone marks typically enriched in active
promoters (H3K4me3) and transcriptional regulatory ele-
ments (H4K3me1 and H3K27Ac) (Figure 1A). To evalu-
ate the promoter activity of this region, we cloned the ge-
nomic sequence located between −534 and +297 bp from
the TSS upstream of the luciferase reporter gene and trans-
fected it into HEK293T cells. The putative promoter re-
gion of Sam68 displayed higher activity to that of the hu-
man HNRPA1 promoter, while being significantly weaker
than the viral SV40 promoter (Figure 1B). No transcrip-
tional activity was observed with an intergenic DNA region
of the same length. Progressive deletion mutants indicated
that the region between−130 bp and +297 bp from the TSS
is required for the optimal activity of the Sam68 promoter
(Figure 1C). These results suggest that a relatively small ge-
nomic region acts as promoter for Sam68 expression in hu-
man cells.
To identified transcription factors that potentially bind
cis-regulatory DNA elements in the Sam68 promoter, we
queried the HMRConserved Transcription Factor Binding
Sites, the ENCODE Transcription Factor Binding Tracks
datasets and ChIP-seq experiments deposited in the UCSC
Genome Browser database. Among others, we found two
potential binding sites for the oncogenic transcription fac-
tor c-MYC that are located at −64 and −45 bp from the
Sam68 TSS (Supplementary Figure S1B), within the region
required for optimal transcriptional activity (Figure 1C).
Analysis of ChIP-seq experiments in multiple cell lines (En-
code Project, https://www.encodeproject.org) confirmed the
binding of c-MYC to the Sam68 promoter region (Figure
1D and Supplementary Figure S1C), suggesting a direct
regulation of Sam68 expression by this transcription factor
in cancer cells.
Sequence analysis of the Sam68 promoter high-
lighted two perfect c-MYC consensus E-box binding sites
(CACGTG; Supplementary Figure S2A). To directly
test whether c-MYC regulates Sam68 transcription, we
performed ChIP experiments in LNCaP cells, an androgen-
sensitive PCa cell line expressing high levels of Sam68 (14).
Semiquantitative (sqPCR) and quantitative (qPCR) PCR
analyses detected a significant enrichment of c-MYC in
the promoter region of Sam68 (Figure 2A and B), which
was comparable to that observed for other c-MYC targets,
such as cyclin B1, nucleolin (25) and hnRNP A1 (26). By
contrast, no binding was observed in the intergenic (16q22)
control region of chromosome 16, indicating specificity of
binding (Figure 2A and B).
Next, we tested whether c-MYC modulates Sam68
expression. Co-transfection of the Sam68 promoter
reporter and c-MYC resulted in significant induc-
tion (∼2-fold) of the luciferase activity (Figure 2C),
which was comparable to that observed with the hn-
RNPA1 promoter (Figure 2C and Supplementary Figure
S2B). Individual (Mut1: CACGTG→AAAGTA; Mut2:
CACGTG→AAAGTT) or double mutation (Mut1-2:
CACGTG/CACGTG→AAAGTA/AAAGTT) of the
putative E-box binding sites significantly impaired c-MYC-
dependent activation of the Sam68 promoter (Figure 2C
and Supplementary Figure S2C), with Mut1 causing the
greatest influence. Interestingly, the double mutant (Mut1-
2) did not show additive effect (Figure 2C), suggesting
that c-MYC activity primarily relies on E-Box1 and that
additional regions participate to regulation.
The c-MYC transcriptional activity often relies on its
functional interaction with the co-regulator MAX (27).
Thus, we also tested their possible cooperation on the regu-
lation of Sam68 expression. Under sub-optimal conditions
(24 h after transfection),MAXdid not affect Sam68 expres-
sionwhen overexpressed alone, but it significantly enhanced
the transcriptional activity of c-MYC on the Sam68 pro-
moter in co-transfected cells (Supplementary Figure S2D).
Collectively, these findings identify c-MYC as a direct reg-
ulator of Sam68 transcription.
c-MYC positively regulates Sam68 expression in prostate
cancer
To test whether Sam68 expression is under the control of
c-MYC in PCa cells, we knocked down its expression in
four PCa cell lines (LNCaP, 22RV1, PC3 and DU145) us-
ing two pools of siRNAs (siRNA#1 and #2). c-MYCdeple-
tion caused a significant reduction in Sam68 expression at
both mRNA and protein levels (Figure 3A–D), which was
comparable to that exerted on hnRNPA1 (26) (Supplemen-
tary Figure S3A–D). These results indicate that c-MYCpro-
motes Sam68 expression in PCa cells.
The pro-oncogenic role of c-MYC mainly relies on
regulation of gene expression programs (28), including
genes encoding core spliceosome components (29) and pro-
oncogenic splicing factors (19,26). Since upregulation of
both c-MYC (16,30) and Sam68 (14,15) have been reported
in PCa, we asked whether their expression levels correlated
in patients by analyzing public datasets (R2 genomics; http:
//r2.amc.nl). Pearson’s correlation analysis using the Jenk-
ins PCa dataset (GSE46691) deposited in R2 genomics (16)
revealed a positive correlation (P< 0.0001) between c-MYC
and Sam68 expression (Figure 3E). Similar positive corre-
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Figure 1. Identification of the Sam68 promoter region. (A) UCSC Genome Browser snapshot of RNAPII, H3K27Ac, H3K4Me1 and H3K4Me3 ChIP-
seq profiles and Chromatin State Segmentation of the Sam68 locus, including an ∼20 Kbp upstream intergenic region. Chromatin state segmentation
(colored rectangles; state 1–11) and cell lines (colored squares; List subtracks) are indicated. (B and C) Bar graphs represent luciferase activity of Sam68,
hnRNP A1 and SV40 promoters compared to an upstream intergenic region (intergenic; −17753 to −16920 bp from the TSS) used as negative control
(B), and of Sam68 promoter deletion mutants (Mut5′A, Mut5′B, Mut5′C, Mut3′A, Mut3′B) compared to the wild-type (wt) and interegenic reporters
(C). A schematic representation of wt and mutant reporters is also shown; the upstream (black line) and downstream (gray line) regions from the Sam68
TSS are indicated (C; left panel). All Luciferase assays were performed in HEK293T 48 h post-transfection. Data represent mean ± SD of three biological
replicates. Statistical significance was calculated by Student’s t-test. *P< 0.05; **P< 0.01; ***P< 0.001; n.s., not significant. (D) Representative ChIP-seq
analysis of c-MYC and RNAPII binding to the Sam68 promoter region in NB4 cells with a schematic representation of the Sam68 gene structure showing
predicted TSS (arrow), introns (horizontal lines) and exons (boxes).
lation between c-MYC and Sam68 expression was found
by analyzing other datasets of PCa patients (GSE21034
and GSE29079) (17,18) (Supplementary Figure S3E and
F). Furthermore, Z-score classification of patients for low
and high expression of c-MYC confirmed that Sam68 lev-
els are significantly higher in the MYChigh compared to the
MYClow group (Figure 3F; Supplementary Figure S3E and
F). These findings suggest a direct link between upregula-
tion of c-MYC and Sam68 transcription in PCa.
c-MYC downregulation impacts on Sam68 expression during
cell growth arrest
Both c-MYC and Sam68 promote PCa cell prolifera-
tion (14,31), whereas cell growth arrest is linked to c-
MYC downregulation (32). Thus, we asked whether Sam68
expression was perturbed under conditions that induce
growth arrest. Serum deprivation of LNCaP cells for 6 days
significantly impaired proliferation, as indicated by a reduc-
tion of BrdU positive cells (Figure 4A). Under these con-
ditions, we also observed concomitant downregulation of
both c-MYC and Sam68 mRNA and protein levels (Fig-
ure 4B and C). Serum deprivation and c-MYC silencing did
not exert additive effects on Sam68 expression (Supplemen-
tary Figure A and B), suggesting that they function in the
same pathway. Notably, a similar concomitant reduction of
c-MYC and Sam68 expression was also observed in PC3
cells induced to growth arrest by serum deprivation (Sup-
plementary Figure S4C–E).
Most PCas maintain dependency on androgens for cell
proliferation and tumor growth. For this reason, inhibi-
tion of AR signaling represents the first-line therapy for
this cancer. Thus, to impair PCa cell growth by an alterna-
tive approach, we treated the androgen-dependent LNCaP
cells with Enzalutamide, a clinically approved AR inhibitor
(2). Exposure of LNCaP cells to 1M Enzalutamide for 6
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Figure 2. c-Myc binds to the Sam68 promoter region. (A) sqPCR and (B) qPCR analyses of ChIP experiments performed in LNCaP cells using c-MYC
antibody and IgG (IgG), or no antibody (no ab), as negative control. Associated DNA is expressed as % of input (B). Schematic representation of the
indicated gene promoters and of the 16q22 intergenic region is shown in (A) (left panel). c-MYCbinding sites (solid box), TSS and primers position for PCR
analyses (arrows) are indicated. (C) The bar graph represents the luciferase assay performed in HEK293T cells transfected with wt or mutated (Mut1,Mut2
and Mut1-2) Sam68 promoter reporters in combination, or not (empty vector, EV), with c-MYC-pCDNA3 vector (c-MYC). A schematic representation
of wt and c-MYC binding site mutants (Mut1, Mut2 and Mut1-2) of the Sam68 promoter is also shown (left panel). (B and C) Data represent mean ± SD
of three biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant (Student’s t-test).
days induced a significant reduction of proliferation (Fig-
ure 4D). Strikingly, also under this condition we observed a
concomitant reduction in Sam68 and c-MYC levels (Figure
4E and F), indicating that the effect was linked to ADT-
mediated growth arrest. As expected, proliferation of the
androgen-insensitive PC3 cells was not affected by Enzalu-
tamide treatment (Supplementary Figure S4F) and neither
c-MYC nor Sam68 expression was significantly modulated
(Supplementary Figure S4G and H). These results suggest
that under adverse growth conditions, PCa cells concomi-
tantly downregulate c-MYC and Sam68 expression to halt
proliferation.
c-MYC affects alternative splicing of Sam68 through modu-
lation of the RNAPII elongation rate
Regulation of exon 3 splicing in the Sam68 transcript has
been previously related to growth conditions (33). Inclusion
of exon 3 generates the full-length variant with an intact
KH domain for RNA binding, whereas skipping of exon
3 generates an isoform that presents a 39-amino acid dele-
tion in this domain (Sam68-KH) (Figure 5A) and is un-
able to bind RNA (34). Although difficult to detect in cell
lines under culture conditions, the Sam68-KH splice vari-
ant was shown to be induced upon growth arrest in non-
transformed fibroblasts (33). We observed an ∼30–50% in-
crease in the levels of the Sam68-KH variant in LNCaP
cells exposed to either serum deprivation or Enzalutamide
treatment, as determined by both sqPCR (Figure 5B) and
qPCR (Figure 5C). These results indicate that growth ar-
rest impacts on Sam68 AS in PCa cells. Since under these
conditions expression of c-MYC is also halted (Figure 4),
we asked whether c-MYC is involved in the Sam68 splic-
ing switch. Strikingly, c-MYC depletion recapitulated the
increase in exon 3 skipping observed under growth arrest in
LNCaP cells (Figure 5DandE), indicating that c-MYCpro-
motes both expression and productive splicing of the Sam68
full length variant.
Transcription and splicing are functionally coupled, and
transcription-related processes influence splicing outcome
(10). For instance, changes in the RNAPII elongation rate
modulate splicing of hundreds of genes (35). Fast RNAPII
elongation rate correlates with its phosphorylation in Ser-
ine 2 (p-Ser2) and we observed that c-MYC depletion re-
duced the levels of this post-translational modification in
LNCaP cells (Figure 5F). Thus, to investigate whether the
transcriptional activity of c-MYC influences Sam68 AS,
we first tested the effect of c-MYC on the RNAPII elon-
gation rate within the Sam68 transcription unit. To this
end, we quantified RNAPII processivity as the ratio be-
tween promoter-distal and promoter–proximal regions of
the Sam68 pre-mRNA at steady state (36). qRT-PCR anal-
ysis using primers located at the exon 1/intron 1 (430 bp
from TSS) and exon 8/intron 8 boundaries (25707 bp from
TSS) revealed a reduction in RNAPII processivity in c-
MYC-depleted LNCaP cells (Figure 5G, steady state and
Supplementary Figure S5A and B). This effect was even
more evident in nascent pre-mRNA analyzed 20 min af-
ter release from the transcriptional block caused by in-
cubation with the RNAPII inhibitor 5,6-dichloro-l-b-D-
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Figure 3. c-MYC regulates Sam68 expression in PCa. (A–D) qPCR (A and C) and western blot (B and D) analyses of Sam68 expression in PCa cells
lines transfected with two different pools of c-Myc (si-cmyc #1 and si-cmyc #2) or control (si-scr #1 and si-scr #2) siRNAs. (A and C) Fold change of
Sam68 expression relative to Histone 3 expression was calculated by the Cq method. Data represent mean ± SD of three biological replicates. *P <
0.05; **P < 0.01 (Student’s t-test). (E) Plot showing Sam68 and c-MYC expression in 545 PCa patients retrieved from the Jenkins (GSE46691) dataset.
Pearson’s correlation coefficient (r) and P-value are reported. (F) Sam68 expression profile in PCa patients (Jenkins-GSE46691) classified according to Z-
score normalization in c-MYClow (blue circles) and c-MYChigh (red squares) expressing group. The dot plot shows distribution and the median (horizontal
line). Statistical significance was calculated by Mann–Whitney test, *** P < 0.001.
ribofuranosylbenzimidazole (DRB) (23). At this time point,
when exon8/intron8 expression in the pre-mRNA reaches a
plateau (Supplementary Figure S5C), depletion of c-MYC
caused a two-fold reduction in RNAPII processivity within
the Sam68 gene (Figure 5G, 20 min post-DRB).
These observations suggest that reduction of theRNAPII
elongation rate may underlie the effect of c-MYC on Sam68
splicing. To test this possibility by an alternative approach,
LNCaP cells were treated with suboptimal doses of DRB to
reduce RNAPII p-Ser2 phosphorylation (Figure 5H) and
its elongation rate without blocking transcription (35). In-
terestingly, we found that splicing of the Sam68-KH iso-
form could be recapitulated in a dose-dependent manner
in LNCaP cells treated with sub-optimal concentrations of
DRB (Figure 5H and I; Supplementary Figure S5D). Simi-
lar results were obtained with two other RNAPII phospho-
rylation inhibitors, flavopiridol and LDC067 (Supplemen-
tary Figure S5E–H). Collectively these results suggest that
the effect of c-MYC on Sam68 exon 3 splicing is mediated
by a change in the RNAPII elongation rate.
A slow RNAPII elongation rate promotes recruitment of hn-
RNP F and skipping of Sam68 exon 3
Changes in the RNAPII elongation rate may induce inclu-
sion or skipping of alternative exons through kinetic or re-
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Figure 4. PCa cell growth arrest concomitantly induces c-MYC and Sam68 downregulation. (A–F) Representative dot plot profiles of cytometric analyses
showing DNA content versus BrdU incorporation in LNCaP cells after 6 days of serum deprivation (A) or 1 MEnzalutamide (D) conditions. Bar graphs
(A and D) represents the percentage of S-phase BrdU positive cells after 6 days of treatment. qPCR (B and E) and western blot (C and F) time-course
analyses of c-MYC and Sam68 expression (1d: 1 day; 3d: 3 days; 6d: 6 days). Fold change of Sam68 and c-MYC expression relative to Histone 3 expression
was calculated by the Cq method. Data represent mean ± SD of three biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant
(Student’s t-test).
cruitment mechanisms (37), non mutually exclusive models
that can also cooperate in splicing regulation (38). In the
first case, a slow elongation offers a window of opportu-
nity to the weaker splice sites before stronger splice sites
of constitutive exons are transcribed. In the recruitment
model, the slower RNAPII is able to recruit splicing regu-
lators to modulate recognition of the alternative exon splice
sites. Since phosphorylation of RNAPII mediates its inter-
action with splicing factors (SFs) during pre-mRNA tran-
scription and processing (39), we hypothesized that reduc-
tion of p-Ser2 phosphorylationmight affect the recruitment
of specific SF(s) to the Sam68 pre-mRNA in addition to
its effects on the elongation rate. To test this hypothesis, we
searched for bindingmotifs of splicing factors within exon 3
and flanking intronic sequences using the SpliceAid 2 (http:
//193.206.120.249/splicing tissue.html) (40) and RBP map
(http://rbpmap.technion.ac.il/) (41) prediction tools (Sup-
plementary Figure S6A). We found several potential bind-
ing sites for Sam68 itself, for c-MYC-regulated members
of the hnRNP family (Supplementary Figure S6A), which
generally act as splicing repressors, and for ETR-3, a splic-
ing repressor that was recruited by slow RNAPII (38). To
test whether these splicing factors could modulate exon
3 splicing, we constructed a minigene encompassing the
whole alternatively spliced region of Sam68, from exon 2 to
exon 4 including intervening introns (Supplementary Fig-
ure S6B). Splicing assays in HEK293T cells indicated that
Sam68 does not regulate its ownAS (Supplementary Figure
S6B), nor this event was regulated by hnRNP A2, hnRNP
I (PTBP1) and ETR-3 (Supplementary Figure S6C). By
contrast, hnRNP A1, hnRNP F and hnRNP H promoted
skipping of exon 3 (Supplementary Figure S6C). More im-
portantly, qPCR analyses revealed that overexpression of
the highly homologous hnRNP F and hnRNPH promoted
exon 3 skipping also in the endogenous Sam68 transcript
in LNCaP cells, whereas hnRNPA1 was ineffective (Figure
6A). Accordingly, hnRNP F/H depletion significantly re-
duced exon 3 skipping in the endogenous Sam68 transcript,
whereas hnRNPA1 knockdown did not (Figure 6B). These
results suggest that hnRNP F/H are strong candidates for
regulation of Sam68 splicing in PCa cells.
c-MYC is known to regulate the expression of several
splicing factors (19,42). Notably, we found that c-MYC de-
pletion in LNCaP cells caused also mild downregulation of
hnRNP F/H expression, in addition to that of its known
targets (Supplementary Figure S6D). Since exon 3 skip-
ping occurred in spite of the slightly reduced levels of hn-
RNP F/H, we asked whether modulation RNAPII elon-
gation rate by c-MYC promoted recruitment of these fac-
tors on the Sam68 pre-mRNA. To test this possibility, we
treated LNCaP cells with DRB, which mimicked the effect
of c-MYCdepletion onRNAPII phosphorylation and exon
3 splicing without significantly affecting expression of hn-
RNP F/H or other c-MYC-regulated splicing factors (Sup-
plementary Figure S6E). CLIP experiments showed that re-
cruitment of hnRNP F to the exon 3 region of the Sam68
pre-mRNA was significantly increased upon DRB treat-
ment (Figure 6C).
DISCUSSION
Sam68 is upregulated and plays key roles in several hu-
man tumors (13), including PCa (14,15). However, despite
its relevance in oncogenic processes, how Sam68 transcrip-
tion is dysregulated in cancer cells remains unknown. Our
study now demonstrates that the oncogenic transcription
factor c-MYC promotes expression and proper splicing of
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Figure 5. c-MYC modulates the AS of Sam68. (A) Diagram showing AS of Sam68. Exons (boxes), introns (horizontal lines) and position (arrows) of
primers used for sqPCR are shown. (B–E) sqPCR (B and D) and qPCR (C and E) analyses of Sam68-KH and KH splicing in LNCaP cells cultured
under serum deprivation condition (0% FBS) or in presence of 1 M Enzalutamide (Enz) (B and C), or transfected with control (si-scr #1 and #2) or
c-MYC (si-myc #1 and #2) siRNAs (D and E). (F) Representative western blot analysis showing the expression level of c-MYC, total (TOT-RNAPII) and
Serine2 (pSer2-RNAPII) RNAPII in LNCaP cells transfected with control (si-scr #1) or c-MYC (si-myc #1) siRNAs. Tubulin was used as loading control.
(G) Bar graphs represent qPCR evaluation of Sam68 exon1-intron1 and exon8–intron8 ratio performed at steady state level (left) and 20min post-DRB
release (right). LNCaP cells transfected with either control (si-scr #1) or c-MYC (si-cmyc #1) siRNAs were treated with 75 M DRB for 6 h and RNA
was extracted 20 min after DRB release. Data are reported as fold change of Sam68 exon1–intron1 relative to exon8–intron8 expression calculated by the
Cq method. A scheme of Sam68 gene and primers position (arrows) used for qPCR is shown. (H and I) sqPCR (H) and qPCR (I) analyses showing
Sam68-KH and -KH ratio in LNCaP cells treated for 12 h with suboptimal DRB concentration. A representative western blot (WB) analysis (H) of the
pSer2-RNAPII and TOT-RNAPII expression levels is also shown. Tubulin was used as loading control. (B, D and H) The Percent of Spliced-In Index
(PSI;  ) is reported below the gels. (C, E and I) Fold change of Sam68-KH expression relative to Sam68-KH expression was calculated by the Cq
method. (B–E, G–I) Mean ± SD of three biological replicates. *P < 0.05; **P < 0.01; ***P < 0.001 (Student’s t-test).
Sam68 mRNA to yield high levels of this protein in PCa
cells. Furthermore, we show that c-MYC and Sam68 ex-
pression are tightly linked to favorable environmental con-
ditions, whereas downregulation of c-MYC under andro-
gen and/or serum deprivation correlates with repression of
Sam68 transcription and exon 3 splicing, yielding a vari-
ant unable to bind RNA (Figure 6D). Thus, our work un-
covers the molecular mechanism underlying dysregulation
of Sam68 expression in PCa, a finding that is probably ex-
tendible to other human cancers in which the c-MYC onco-
gene is upregulated.
To identify potential regulators of Sam68 transcription,
we queried public datasets provided by the Encode project
using theUCSCGenome Browser tool. This unbiased anal-
ysis identified a subset of transcription factors potentially
involved in the regulation of Sam68 expression. Among
them, we focused on c-MYC because of its well-established
oncogenic function in human cancers (43). The activity of
c-MYC profoundly alters the transcriptome of cancer cells
(44). Furthermore, mounting evidence supports a key role
for c-MYC also in the control of splicing, which further di-
versifyies the transcriptome of cancer cells. Indeed, spliceo-
some components (29,45) and splicing factors, including
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Figure 6. hnRNP F modulates the AS of Sam68 exon 3. (A and B) qPCR analyses of in vivo splicing assay performed in LNCaP cells transfected (A) or
depleted (B) for the indicated splicing factors. Bar graphs (A and B; left panels) show the fold change of Sam68-KH expression relative to Sam68-KH
expression calculated by the Cq method. A representative western blot analysis (A and B; right panel) to asses the expression levels of the indicated
splicing factors is shown. -actin was used as loading control. (C) CLIP assays performed in LNCaP cells treated (DRB) or not (DMSO) with 5 g/ml of
DRB to detect the recruitment of hnRNP F on the endogenous Sam68 pre-mRNA. The immunoprecipitation was performed using hnRNP F antibody
or IgGs, as negative control. RNA associated with hnRNP F was quantified by qPCR using primers located at the Sam68 exon 3–intron 3 boundary and
represented as percentage (%) of input. (D) Schematic model for c-MYC-driven Sam68 gene expression and AS regulation. (A–C) Bars represent mean ±
SD of three biological replicates. **P < 0.01; ***P < 0.001; n.s., not significant (Student’s t-test).
SRSF1, PTBP1, hnRNP A1 (19,26) are direct targets of
c-MYC. Notably, SRSF1 expression promotes prolifera-
tion, cell survival and anchorage-independent growth in
several tumors (19) and its phosphorylation by SRPK1 con-
trols angiogenesis through the splicing regulation of VEGF
(46), which is essential in highly vascularized cancers like
PCa (47). On the other hand, the regulation of spliceosome
components is required for c-MYC-driven malignant trans-
formation (29,45), suggesting that safeguarding splicing fi-
delity is a key element for the pro-oncogenic function of
c-MYC. Our study now identifies Sam68 as an additional
splicing regulator under c-MYCcontrol in cancer.We found
a highly significant correlation between c-MYC and Sam68
expression in PCa patients, suggesting that this regulation is
functional in vivo. Although our work was focused on PCa,
it is likely that c-MYC more generally regulates Sam68 ex-
pression in cancer, as ChIP-seq peaks for this transcription
factor within the Sam68 promoter region were found in cell
lines of different origin.
Bioinformatics analyses revealed a relatively small region
upstream of the first Sam68 coding exon that displays pro-
moter features, such as histone marks of active transcrip-
tion and RNAPII occupancy. Since the transcriptional ac-
tivity of this region was confirmed in reporter assays, our
study identifies a core promoter of human Sam68 that is ac-
tive in multiple cell types. Our results also show that c-MYC
mainly acts through binding to two E-boxes proximal to the
TSS. Importantly, c-MYC expression is increased in PCa
and correlates with disease severity (30,48). Since Sam68
and c-MYC upregulation is correlated in PCa patients, our
findings suggest that Sam68 takes part to the oncogenic pro-
gram activated by c-MYC in prostate cells.
c-MYC expression overrides growth arrest and reduces
the capacity of cancer cells to differentiate (32). Sam68 ap-
pears to support the same functions, as its depletion im-
paired PCa cell proliferation (14) and induced neural stem
cell differentiation (49). Thus, we tested the possibility that
the expression of c-MYC and Sam68 responds to favor-
able growth conditions in PCa cells. As expected, we ob-
served a concomitant reduction of c-MYC and Sam68 ex-
pression under conditions that cause proliferation arrest,
such as serum deprivation and inhibition of AR signaling.
These findings suggest the existence of a c-MYC-Sam68
functional axis in PCa and highlight a possible novel role
for Sam68 as mediator of c-MYC function.
The KH domain is crucial for the RNA-binding activ-
ity of Sam68 (34). It was previously reported that a Sam68
splice variant lacking a functional KH domain (Sam68-
KH) is generated upon growth arrest (33) and this variant
was proposed to participate to cell cycle arrest in fibroblasts.
Nevertheless, whether the Sam68-KH variant existed in
cancer cells and the mechanisms underlying its expression
had not been investigated. Sam68-KH results from exon
3 skipping during pre-mRNA splicing. We observed an
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increase in exon 3 skipping upon growth arrest induced
by either serum or androgen deprivation and this effect
was recapitulated by knockdown of c-MYC. Thus, c-MYC
likely controls both transcription and productive splicing
of Sam68. This regulation may have widespread impact
on the transcriptome of PCa cells. Expression of Sam68-
KH may not only impair splicing of the direct Sam68
targets, but also affect those of SRSF1 because Sam68 is
required to inhibit non-sense mediated decay (NMD) of
SRSF1 transcripts (50). These observations suggest that the
c-MYC- mediated oncogenic program may also rely on a
widespread splicing program empowered by the network of
cross-regulation between its downstream effectors. Since c-
MYC lacks molecular features that can be targeted by small
molecule inhibitors, identification of downstream effectors
may help develop treatments for MYC-driven cancers. For
instance, antisense oligonucleotides (ASOs) targeting splic-
ing of Sam68 exon 3mayweaken the c-MYConcogenic pro-
gram in PCa and enhance the efficacy of other anti-cancer
treatments.
Mechanistically, we linked c-MYC action to modulation
of RNAPII activity. Since c-MYC influences RNAPII oc-
cupancy across the transcribed unit of its target genes, as
well as phosphorylation ofRNAPII at Serine 2 (51), c-MYC
might alter Sam68 splicing by affecting the RNAPII elon-
gation rate within the locus. Indeed, we found that depletion
of c-MYC decreased Ser-2 phosphorylation of RNAPII in
LNCaP cells and reduced the RNAPII elongation rate in
the Sam68 gene, which correlated with exon 3 skipping. In
our experiments RNAPII processivity was calculated as ra-
tio of regions in the same transcript, thus it should be in-
dependent of the total amount of transcript produced by
the gene. Nevertheless, since transcription efficiency and
RNAPII processivity are mechanistically linked (39), they
could impact on each other and we cannot completely dis-
tinguish between these two aspects affected by c-MYC.
However, the effect on Sam68 splicing could be recapitu-
lated by treatment of cells with several CDK9 inhibitors.
Thus, our results suggest that reducing the RNAPII elonga-
tion rate is sufficient for exon 3 splicing regulation and that
c-MYC coordinates transcription and splicing of Sam68 by
affecting the RNAPII elongation rate.
Changes in RNAPII dynamics can affect splicing by af-
fecting recruitment of specific splicing factors to the reg-
ulated exons (37). Such model was recently demonstrated
for the CFTR gene, where reduced RNAPII processivity al-
lowed recruitment of the splicing repressor ETR-3 and pro-
moted exon skipping (38). Herein, by performing bioinfor-
matics analyses and splicing assays, we identified hnRNP
F as a regulator of Sam68 exon 3 splicing, whose recruit-
ment to the pre-mRNA is favored by a slow RNAPII in
PCa cells. We focused on hnRNP F because its antibody
functioned better than that of hnRNP H under CLIP con-
ditions in LNCaP cells. However, given their high homol-
ogy, this antibody also partially recognizes hnRNP H and
it is likely that exon 3 skipping is due to binding of both
hnRNPs to the Sam68 transcript.
In conclusion, our study reveals that c-MYC contributes
to regulation of Sam68 transcription and productive splic-
ing in PCa cells through modulation of RNAPII dynamics
within the gene.
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